Effects of hormone replacement therapy on blood platelets

European Journal of Clinical Investigation

Volumn 32, Issue 8, 2002, Pages 613-618

  Thijs, A ^a,b   Van Baal, W M ^a,b   Van Der Mooren, M J ^a,b   Kenemans, P ^a,b   Drager A M ^a   Huijgens, P C ^a   Stehouwer, C D A ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Hormone replacement therapy; Hormones; Menopause; Platelet activation

Indexed keywords

DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; GLYCOPROTEIN; HORMONE; PADGEM PROTEIN; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYSTERECTOMY; LYSOSOME; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANTIGENS, CD; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; PROGESTERONE CONGENERS; PROMEGESTONE; PROSPECTIVE STUDIES;

EID: 0037002683     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01039.x     Document Type: Article

References (36)

1. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981;i:858-60.
2. Newton KM, LaCroix AZ, McKnight B, Knopp RH, Siscovick DS et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997;145:269-77.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
4. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
5. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
6. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998;179:S62-S67.
7. Heckbert SR, Kaplan RC, Weiss NS, Psaty BM, Lin D et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001;161:1709-13.
8. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. Ann Intern Med 2001;135:1-8.
9. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000;83:29-34.
10. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
11. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991;65:467-73.
12. Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998;79:885-96.
13. Michelson AD, Shattil SJ. The use of flow cytometry to study platelet activation. In: Watson SP, Authi KS, editors. Platelets, a Practical Approach. Oxford: IRL Press, 1996.
14. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997;134:764-71.
15. Ranganath LR, Christofides J, Semple MJ. Increased mean platelet volume after oestrogen replacement therapy. Ann Clin Biochem 1996;33:555-60.
16. Ranganath LR, Christofides JA, Wright JW, Marks V. Effects of hormone replacement therapy on platelet membrane fatty acid composition. J Endocrinol 1996;148:207-12.
17. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993;81:261-4.
18. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998;69:883-8.
19. Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998;69:267-73.
20. Mene P, Pecci G, Cinotti GA, Pugliese G, Pricci F, Pugliese F. Eicosanoid synthesis in peripheral blood monocytes: a marker of disease activity in lupus nephritis. Am J Kidney Dis 1998;32:778-84.
21. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am 1990;4:1-26.
22. Colman RW. Platelet receptors. Hematol Oncol Clin North Am 1990;4:27-42.
23. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
24. van Baal WM, Emeis JJ, Kenemans P, Kessel H, Peters-Muller ER et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999;29:913-21.
25. van Baal WM, Kenemans P, Emeis JJ, Schalkwijk CG, Mijatovic V et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999;71:663-70.
26. Chang WC, Nakao J, Orimo H, Tai HH, Murota SI. Stimulation of 12-lipoxygenase activity in rat platelets by 17 beta-estradiol. Biochem Pharmacol 1982;31:2633-8.
27. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000;95:2289-96.
28. Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 1998;35:241-52.
29. Cavenagh JD, Cahill MR, Kelsey SM. Adhesion molecules in clinical medicine. Crit Rev Clin Lab Sci 1998;35:415-59.
30. Nieuwenhuis HK, van Oosterhout JJ, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53 000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987;70:838-45.
31. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999;95:1-18.
32. Michelson AD, Benoit SE, Kroll MH, Li JM, Rohrer MJ et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994;83:3562-73.
33. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
34. van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999;81:925-8.
35. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22.
36. Frojmovic MM. Platelet aggregation in flow: differential roles for adhesive receptors and ligands. Am Heart J 1998;135:S119-S131.